External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology ICML 2025
Roche and Genentech at

ICML 2025

June 17 - June 21
Lugano, Switzerland / Virtual (Hybrid)
icml.ch
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
06:00 AM
Duration 60mins Lugano, Switzerland
Circulating Tumor DNA (ctDNA) at Screening as a Prognostic Marker in Untreated Follicular Lymphoma from the GALLIUM Trail Using a Next Generation Sequencing (NGS) Assay
Corinna Lutterbeck
Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:00 PM
Duration 90mins Lugano, Switzerland
Deciphering treatment in DLBCL: Choosing the right therapy for the right patient now and beyond
Dr Wendy Osborne (Chair), Prof. Jeremy Abramson, Prof. Michael Dickinson
Haematology - Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:30 PM
Duration 90mins Lugano, Switzerland
Bispecific antibodies: Advances in the treatment of relapsed/refractory follicular lymphoma
Sehn L, Scholz C, Eyre T, Casulo C
Haematology - Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:50 PM
Duration 15mins Room A
Polatuzumab vedotin▼, rituximab, gemcitabine and oxaliplatin (Pola-R-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase III POLARGO trial
Sancho J-M, Li Z, Vassilakopoulos TP, Viardot A, McMillan A, Dal MS, Pereira J, Kim JS, Qiu L, Batlevi CL, Ibrahim R, Hernandez J, McCall B, Jiang Y, Yan M, Harris W, Musick L, Haioun C, Matasar M
Haematology - Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:30 PM
Duration 10mins Room A
Fixed duration subcutaneous mosunetuzumab▼ in patients with previously untreated high-tumor burden follicular lymphoma: interim results from the Phase II MorningSun study
Budde LE, Burke JM, Sharman JP, Anz B, Zuniga R, Tun AM, Jani P, Biondo JML, Wu M, Mun Y, Chopra VS, Farighi R, Lin T, Villasboas JC, Flinn IW
Haematology - Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:30 AM
Duration 30mins Lugano, Switzerland
Safety and efficacy of mosunetuzumab▼ subcutaneous maintenance following mosunetuzumab▼ plus lenalidomide induction therapy in previously untreated follicular lymphoma
Eyre TA, Cordoba R, Patel K, Serna A, Houot R, Bishton M, Zhang H-L, Zou L, Galvez-Carvajal L, Osborne W, Bachy E, Thieblemont C, Knapp A, Sit J, Chang N, Chen V, Penuel E, Wei MC, Purev E, Morschhauser F
Haematology - Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 30mins Lugano, Switzerland
Fixed-duration subcutaneous mosunetuzumab▼ in patients with relapsed/refractory (R/R) follicular lymphoma (FL) with high-risk features: pivotal Phase II study update
Sehn LH, Budde LE, Assouline S, Giri P, Kuruvilla J, Schuster SJ, Yoon S-S, Fay K, Hess G, Dreyling M, Gutierrez NC, Cybulski E, Kwan A, Penuel E, Tracy S, Kuruvilla D, Chen J, Wiebking V, Wei MC, Bartlett NL
Haematology - Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 30mins Lugano, Switzerland
Machine learning based unsupervised multimodal analysis identifies patient subsets associated with response to mosunetuzumab▼ in relapsed/refractory NHL
Hamidi H, Diaz G, Tracy S, Yin S, Wei MC, Penuel E
Haematology - Oncology | Non Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:00 PM
Duration 10mins Auditorium
Glofitamab▼ plus R-ICE or as monotherapy in children and adolescents with relapsed/refractory B-cell non-Hodgkin lymphoma: updated analysis from the iMATRIX-GLO study
Minard-Colin V, Vinti L, San Simon AR, Kang HJ, Ducassou S, Tuckuviene R, Gamel K, Wulff J, Tchaleu FB, Negricea R, Wulff B, Burkhardt
Haematology - Oncology | Non Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:45 PM
Duration 15mins Room A
Fixed-duration outpatient subcutaneous mosunetuzumab▼ + polatuzumab vedotin▼ shows robust efficacy in a Phase II study of relapsed/refractory post-BTKi mantle cell lymphoma
Budde LE, Kamdar M, Assouline S, Ghosh N, Naik S, Nakhoda SK, Chavez J, Ollila TA, Hodson D, Modi D, Bastos-Oreiro M, Ead W, To I, Pham S, Wang J, Wu H, Makadia S, Batlevi CL, Wei MC, Wang ML
Haematology - Oncology | Mantle Cell Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:35 PM
Duration 10mins Polivalente Room
Glofitamab▼+R-CHOP in patients with previously untreated large B-cell lymphoma defined as high risk by circulating tumor DNA (ctDNA) dynamics: primary results
Nijland M, Jardin F, Haioun C, Wrobel T, Joergensen J, Bastos-Oreiro M, Mou E, Lopez JM, Budde LE, Bartlett N, Zaucha J, Garcia-Sancho AM, Relf J, Kirk S, Jiang Y, Berthier A, Tandon M, Doral M, Falchi L
Haematology - Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:30 AM
Duration 30mins Lugano, Switzerland
Mosunetuzumab▼ demonstrates durable clinical benefit in patients (pts) with complete response (CR) and high-risk relapsed/refractory (R/R) follicular lymphoma (FL)
Cheah CY, Bartlett NL, Matasar M, Schuster SJ, Assouline S, Sehn LH, Kuruvilla J, Giri P, Shadman M, Ku M, Hess G, Gregory GP, Kim WS, Wei MC, Yin S, Sit J, Tracy S, Sabalvaro F, Penuel E, Budde LE
Haematology - Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 30mins Lugano, Switzerland
Glofitamab▼ combined with R-CHOP or Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): final results from the NP40126 study
Topp MS, Tani M, Dickinson M, Ghosh N, Santoro A, Pinto A, Bosch F, Fox CP, Guillermo AL, Gastinne T, Viardot A, Townsend W, Cordoba R, Tilly H, Baumlin P, Berthier A, Kirk S, Wu C, Barrett M, Morschhauser F
Haematology - Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 30mins Lugano, Switzerland
Genomic profiling of extranodal (EN) disease in patients (pts) with diffuse large B-cell lymphoma (DLBCL): A combined analysis of POLARIX and GOYA
Lue JK, Morschhauser F, Tilly H, Lenz G, Jardin F, Herrera AF, Sharman JP, Flowers CR, Friedberg JW, Trněný M, Herbaux C, Yan M, Chohan S, Sugidono M, Wang L, Jiang Y, Batlevi CL, Leung W, Harris W, Salles G, Sehn LH
Haematology - Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 30mins Lugano, Switzerland
Real-world safety and efficacy of Pola-R-CHP in patients with previously untreated DLBCL: analysis of 500 patients in the POLASTAR study
Nakamura N, Rai S, Sawa H, Miyawaki K, Satake A, Suzuki R, Fujiwara Y, Nagate Y, Ota S, Fujino T, Goto H, Fukuhara N, Sakata-Yanagimoto M, Izutsu K, Nishikori M, Shibayama H, Kumode T, Ennishi D, Shimose T, Inubashiri N, Matsumura I, Akashi K, Kato K
Haematology - Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 30mins Lugano, Switzerland
Five-year analysis of an Asia subpopulation with previously untreated DLBCL confirms Pola-R-CHP benefit on outcomes: the POLARIX study
Song Y, Tilly H, Rai S, Zhang H, Jin J, Goto H, Ogawa Y, Shin H-J, Kim WS, Cao J, Eom HS, Yoon DH, Tsai XC-H, Gau J-P, Maruyama D, Zhang L, Song Y, Yang Y, Li W, Huang H, Okumura H, Salles G, Sehn LH, Bu L, Jiang Y, Chohan S, Sugidono M, Batlevi CL, Yan M, Xu C, Huang S, Li W, Zhang Y, Zhu J, Izutsu K
Haematology - Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:30 PM
Duration 15mins Room A
Glofitamab▼ plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of STARGLO
Abramson JS, Ku M, Hertzberg M, Fox CP, Herbaux C, Huang H-Q, Yoon DH, Kim WS, Zhang H, Abdulhaq H, Townsend W, Mulvihill E, Ta R, Huang H, Kellemeijn MJ, Belousov A, Bottos A, Lundberg L, Gregory GP
Haematology - Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:30 PM
Duration 15mins Lugano, Switzerland
Mosunetuzumab▼ plus polatuzumab vedotin▼ is superior to R-GemOx in transplant-ineligible patients with R/R LBCL: primary results of the Phase III SUNMO trial
Westin J, Zhang H, Kim W, Fogliatto LM, Rego E, Maruyama D, Rego RM, Farias DLC, Norasetthada L, Hong H, Ozcan M, Jeon Y-W, Pavlovsky A, Goto H, Olszewski A, Shah N, Hu B, Yin S, Janousek M, Wang J, Batlevi CL, Wei MC, Budde E
Haematology - Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.